Skip to main content
    N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $165.92
    +0.61 (+0.37%)

    Market Cap: $16.73B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Neurocrine Biosciences Inc (NBIX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Neurocrine Biosciences (NBIX) has a market cap of $16.73B and an enterprise value of $16.09B. Revenue grew 37.98% over the last 12 months from the 12 months before. Its trailing P/E of 18.5x is below its 5-year median of 24.7x.

    Total Valuation

    Enterprise value is 3.83% below the market cap, as cash exceeds debt.

    Market Cap$16.73B
    Enterprise Value$16.09B
    Latest price (Nov 17, 2026)$165.92

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.59% in the quarter ended Sep 30, 2026 and grew 0.25% a year over 2 years.

    Shares Outstanding101.60M
    Shares Change (YoY)+2.21%
    Shares Change (QoQ)+0.59%
    Share Count Growth (2Y CAGR)+0.25%

    Valuation Ratios

    Sales and book value multiples are 4.6x and 4.3x. Its year-end P/E ranged from 21.6x to 420.1x from 2018 to 2025.

    P/E Ratio18.5x
    Forward P/E22.1x
    P/S Ratio4.6x
    Forward P/S4.2x
    P/B Ratio4.3x
    P/TBV Ratio14.2x
    P/FCF Ratio16.3x
    P/OCF Ratio15.7x
    PEG Ratio0.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 17.0x EBITDA and 15.7x free cash flow.

    EV / Earnings22.9x
    EV / Sales4.3x
    EV / EBITDA17.0x
    EV / FCF15.7x

    Price Statistics

    The stock is up 14.54% over 52 weeks and trades 11.36% above its 50-day average.

    Beta (1Y)0.67
    52-Week Change+14.54%
    1-Month Change+21.13%
    3-Month Change+6.67%
    6-Month Change+7.49%
    5-Year Change+38.60%
    10-Year Change+233.79%
    Total Return (1Y)+14.54%
    Total Return (3Y CAGR)+15.05%
    Total Return (5Y CAGR)+13.66%
    Return vs SPY (1Y)+8.13%
    Max Drawdown (1Y)-27.15%
    Max Drawdown (3Y)-42.89%
    Sharpe Ratio (1Y)0.52
    Correlation with SPY (1Y)0.27
    50-Day Average$148.99
    200-Day Average$149.17
    52-Week Range$122.14 to $186.12
    RSI (14 Days)61.9
    Average Volume (20 Days)1.45M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.04x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio2.04x
    Quick Ratio1.97x
    Debt / Equity0.00x
    Interest Coverage3.85x

    Returns and Efficiency

    Return on equity is 18.11% over the last 12 months, against a 5-year average of 10.93%.

    Return on Equity (ROE)18.11%
    Return on Assets (ROA)12.48%
    ROE (5Y Average)10.93%
    ROA (5Y Average)7.61%
    ROIC (5Y Average)9.60%
    Asset Turnover0.75x
    Inventory Turnover0.37x
    Receivables Turnover4.01x
    Cash Conversion Cycle-8984 days

    Taxes

    Income tax took 24.63% of pretax income over the last 12 months.

    Income Tax (TTM)$229.60M
    Effective Tax Rate24.63%

    Scores

    NBIX has an Altman Z-Score of 7.38, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score7.38
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $3.70B over the last 12 months.

    Revenue$3.70B
    Revenue Growth (YoY)+37.98%
    Gross Profit$3.67B
    Operating Income$887.10M
    Pretax Income$932.10M
    Net Income$702.50M
    EBITDA$953.40M
    Reported EPS (TTM)$8.96

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 68.92% of the $5.63B in total assets.

    Cash and Equivalents$641.50M
    Total Debt$0
    Net Cash$641.50M
    Net Cash Per Share$6.31
    Working Capital$1.02B
    Shareholder Equity$3.88B
    Book Value Per Share$38.18
    Tangible Book Value$1.19B
    Tangible Book Per Share$11.68
    Total Assets$5.63B
    Total Liabilities$1.75B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $30.90M of capital spending, operating cash flow left $1.03B of free cash flow.

    Operating Cash Flow$1.07B
    Capital Expenditures$30.90M
    Free Cash Flow$1.03B
    FCF Per Share$10.18
    Depreciation and Amortization$93.60M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 23.96%, against a 5-year average of 16.99%.

    Gross Margin99.15%
    Operating Margin23.96%
    Pretax Margin25.18%
    Net Margin18.98%
    EBITDA Margin25.76%
    FCF Margin27.96%
    Gross Margin (5Y Average)98.36%
    Operating Margin (5Y Average)16.99%
    Net Margin (5Y Average)12.55%

    Growth

    Revenue grew 24.32% a year over 3 years, and EPS 22.75% a year.

    Revenue Growth (3Y CAGR)+24.32%
    Revenue Growth (5Y CAGR)+22.29%
    EPS Growth (3Y CAGR)+22.75%
    EPS Growth (5Y CAGR)+9.21%
    FCF Growth (3Y CAGR)+32.36%
    FCF Growth (5Y CAGR)+28.04%
    Operating Income Growth (3Y CAGR)+35.47%
    Book Value Per Share Growth (2Y CAGR)+20.61%
    Tangible Book Per Share Growth (2Y CAGR)+21.38%

    Revenue and profit by year

    Dividends and Yields

    NBIX does not pay a dividend. Its free cash flow yield is 6.14%.

    Earnings Yield5.41%
    FCF Yield6.14%
    Buyback Yield-0.08%
    Shareholder Yield-0.08%

    Peer Position

    Against 10 similar companies, NBIX has the 6th highest P/E.

    P/E Ratio18.5x vs 19.6x median
    P/S Ratio4.6x vs 3.0x median
    Revenue Growth (Trailing 4 Quarters, YoY)+37.98% vs +8.88% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 26.56% and EPS growth at 38.63% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+26.56%
    EPS Growth Forecast (2Y CAGR)+38.63%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NBIX

    What is NBIX's market cap?

    Neurocrine Biosciences has a market cap of $16.73B. Its enterprise value, which adds debt and subtracts cash, is $16.09B.

    What is NBIX's P/E ratio?

    Neurocrine Biosciences has a trailing P/E ratio of 18.5x and a forward P/E of 22.1x.

    How many shares of NBIX are outstanding?

    Neurocrine Biosciences has 101.60M shares outstanding. The count is up 2.21% from a year earlier.

    Does NBIX pay a dividend?

    No. Neurocrine Biosciences does not pay a dividend.

    How much debt does NBIX have?

    Neurocrine Biosciences has $0 of total debt and $641.50M of cash and equivalents, a net cash position of $641.50M.